Stock Analysis

Insider Buying: The 2cureX AB (publ) (STO:2CUREX) Chief Executive Officer Just Bought 129% More Shares

OM:2CUREX
Source: Shutterstock

Whilst it may not be a huge deal, we thought it was good to see that the 2cureX AB (publ) (STO:2CUREX) Chief Executive Officer, Fernando Andreu, recently bought kr136k worth of stock, for kr7.15 per share. While that isn't the hugest buy, it actually boosted their shareholding by 129%, which is good to see.

See our latest analysis for 2cureX

Advertisement

2cureX Insider Transactions Over The Last Year

In fact, the recent purchase by Fernando Andreu was the biggest purchase of 2cureX shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at around the current price of kr7.20. That means they have been optimistic about the company in the past, though they may have changed their mind. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the 2cureX insiders decided to buy shares at close to current prices.

While 2cureX insiders bought shares during the last year, they didn't sell. The average buy price was around kr8.79. I'd consider this a positive as it suggests insiders see value at around the current price, which is kr7.20. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
OM:2CUREX Insider Trading Volume April 28th 2023

2cureX is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that 2cureX insiders own 31% of the company, worth about kr40m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Do The 2cureX Insider Transactions Indicate?

It is good to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of 2cureX we think they are probably pretty confident of a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing 2cureX. Be aware that 2cureX is showing 4 warning signs in our investment analysis, and 2 of those are potentially serious...

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.